Why Overseas MAHs Should Not Rely Solely on Their Chinese Distributor: The Case for Annual Compliance Audits
Why should overseas MAHs audit their Chinese distributors annually? Learn how independent distributor audits strengthen China regulatory compliance, quality oversight, pharmacovigilance, and MAH governance.
For many overseas pharmaceutical companies entering the Chinese market, appointing a local distributor is a practical and often necessary step.
A local partner can provide valuable support with:
Importation and distribution
Market access
Customer relationships
Regulatory communication
Product logistics
Local commercial activities
Post-marketing information collection
However, there is an important distinction between appointing a local partner and maintaining effective oversight of that partner.
For an overseas MAH, outsourcing activities to a Chinese distributor does not eliminate the MAH's regulatory responsibilities.
In fact, the more critical activities that are delegated to a local partner, the more important structured and independent oversight becomes.
This is why an annual China distributor audit should be considered an essential component of an overseas MAH's quality and compliance strategy.
A Local Distributor Is a Business Partner — Not a Substitute for MAH Oversight
One of the most common assumptions among overseas companies is:
"We have worked with our Chinese distributor for many years, so we know they are compliant."
Long-term cooperation can certainly provide valuable business continuity.
However, familiarity should not be confused with effective quality oversight.
A distributor's:
Personnel
Quality system
Warehousing arrangements
IT systems
Subcontractors
Business model
Regulatory responsibilities
can all change over time.
A company that was fully capable five years ago may have a very different risk profile today.
Regulatory expectations can also evolve.
Therefore, previous performance is not sufficient evidence of continuing compliance.
What Does Chinese Regulation Expect from Overseas MAHs?
China's Drug Administration Law places responsibility for drug safety, efficacy, and quality management on the MAH.
For an overseas MAH, Article 38 requires the designation of an enterprise legal person within China to fulfill the MAH's obligations and assume joint liability.
The regulatory framework also makes clear that MAHs are expected to maintain oversight of outsourced activities.
Article 31 requires MAHs to regularly audit the quality management systems of drug distributors to supervise and ensure their continuing quality assurance and control capabilities.
This is an important principle for overseas pharmaceutical companies:
Delegating an activity does not mean delegating ultimate accountability.
The distributor may perform the operational activity, but the MAH still needs a mechanism to demonstrate that the activity is appropriately controlled.
Why Annual Distributor Audits Are Necessary
An annual audit is not simply a "tick-box" compliance exercise.
It provides the MAH with an objective opportunity to confirm that its Chinese partner continues to have the appropriate:
Organization
Personnel
Quality systems
Procedures
Training
Documentation
Facilities
Data management controls
Risk management processes
to perform its assigned responsibilities.
Regular audits also create a documented evidence trail showing that the MAH actively monitors its critical outsourced activities.
For overseas companies, this evidence can become particularly valuable during:
NMPA inspections
Internal corporate audits
Partner qualification reviews
Quality investigations
Pharmacovigilance audits
Regulatory submissions
Product lifecycle management
Five Hidden Risks of Relying Solely on a Chinese Distributor
1. The Distributor May Have Changed Since Initial Qualification
Distributor qualification is often performed when the product first enters China.
But businesses evolve.
Since the original qualification audit, the distributor may have experienced:
Management changes
Staff turnover
New warehouses
New subcontractors
IT system changes
Changes in distribution volume
Changes in product portfolio
Changes in regulatory responsibilities
Without periodic reassessment, the original qualification may no longer reflect the distributor's current capabilities.
An annual audit provides an opportunity to reassess whether the partner remains suitable.
2. Quality Systems May Exist on Paper but Not in Practice
A distributor may have comprehensive SOPs, quality manuals, training procedures, and organizational charts.
But the critical question is:
Are these systems actually working?
A quality audit should therefore examine evidence rather than relying solely on documented procedures.
For example:
Are temperature excursions properly investigated?
Are complaints escalated according to procedure?
Are distribution records complete and traceable?
Are personnel actually trained before performing critical activities?
Are deviations investigated appropriately?
Are CAPAs implemented and verified effectively?
The difference between documented compliance and operational compliance can only be evaluated through effective oversight and audit.
3. Pharmacovigilance Responsibilities Can Fall Through the Gap
For pharmaceutical products, one of the highest-risk areas is pharmacovigilance.
A distributor may receive safety information from:
Healthcare professionals
Patients
Hospitals
Medical representatives
Customer service teams
Commercial partners
The critical question is whether this information reaches the MAH's PV system completely, accurately, and within the required timeframe.
Potential weaknesses include:
Delayed transmission of adverse event information
Incomplete case information
Poor documentation of follow-up
Lack of employee awareness of PV reporting requirements
Unclear escalation responsibilities
Insufficient training of sales and customer-facing personnel
A distributor audit should therefore include an assessment of the PV interface between the distributor and the MAH.
The objective is not simply to confirm that an agreement exists, but to verify that the agreed process actually works.
4. Subcontracting Can Create an Invisible Risk Layer
A particularly important issue is subcontracting.
Your contracted distributor may not perform every activity itself.
For example, it may use third parties for:
Warehousing
Transportation
Cold-chain logistics
Customer service
Call centers
Information technology
Other operational support
This creates a potential "four-party" risk structure:
Overseas MAH → Chinese Distributor → Subcontractor → Actual Activity
If the MAH only audits its direct distributor without understanding the subcontracting structure, important risks may remain invisible.
China's regulatory framework requires appropriate oversight when activities such as storage and transportation are outsourced, including assessment of the third party's quality assurance and risk management capabilities.
An effective distributor audit should therefore ask:
Who actually performs the activity?
Has the subcontractor been qualified?
Is there an appropriate quality agreement?
Who monitors the subcontractor?
Are deviations communicated to the MAH?
Can records be retrieved when required?
5. Regulatory Responsibilities May Be Misunderstood
Perhaps the most significant risk is a fundamental misunderstanding of roles.
A distributor may consider itself primarily responsible for:
"selling and delivering the product."
The overseas MAH, however, may expect the distributor to support a much broader range of activities involving:
Regulatory compliance
Product quality
Complaint handling
Pharmacovigilance
Recall support
Risk management
Regulatory communication
Documentation and record retention
If responsibilities are not clearly defined, gaps can occur between the commercial organization and the MAH's global quality system.
A strong quality agreement and clearly defined responsibility matrix are therefore essential.
What Should an Annual China Distributor Audit Cover?
An effective annual audit should be risk-based, rather than simply repeating the same checklist every year.
Depending on the scope of the distributor's responsibilities, an audit may cover:
Quality Management System
Quality organization
SOP management
Training
Deviation management
CAPA
Change control
Internal audits
Management review
Distribution and GDP/GSP Compliance
Warehouse management
Temperature control
Transportation
Stock management
Product traceability
Returns
Recall management
Product destruction
China's Good Supply Practice (GSP) framework requires drug distributors to establish quality management systems and conduct internal audits regularly, including when significant changes occur in key elements of the quality system.
Pharmacovigilance
Adverse event awareness
PV training
Case escalation
Safety information transmission
Complaint/PV interface
Follow-up mechanisms
Reconciliation processes
Product Quality Complaints
Complaint intake
Investigation
Escalation
Root cause analysis
CAPA
Trending
Regulatory and MAH Responsibilities
Regulatory communication
Documentation control
Annual reporting support
Product information management
Recall support
Cooperation with regulatory inspections
Third-Party Oversight
Subcontractor qualification
Quality agreements
Performance monitoring
Audit arrangements
Change notification
Annual Audit Does Not Mean "Audit Everything Every Year"
A common concern among overseas MAHs is the cost of auditing every Chinese partner every year.
A risk-based approach can make annual oversight much more efficient.
For example:
High-Risk Partners
Consider a comprehensive annual audit where the distributor:
Handles critical PV activities
Manages cold-chain products
Has significant regulatory responsibilities
Uses multiple subcontractors
Has experienced significant organizational changes
Handles high-risk products
Medium-Risk Partners
A combination of:
Annual document review + periodic on-site audit
may be appropriate.
Lower-Risk Partners
Remote monitoring, KPI review, quality agreement review, and periodic risk reassessment may complement less frequent on-site audits.
The key principle is:
The audit frequency and scope should reflect the risk — not simply the size of the distributor.
What Should an Overseas MAH Look for During the Audit?
The most valuable distributor audits go beyond checking whether procedures exist.
Auditors should look for evidence of actual performance.
For example:
Instead of asking:
"Do you have a complaint procedure?"
Ask:
"Show us three recent complaints and demonstrate how each one was received, assessed, escalated, investigated, and closed."
Instead of asking:
"Do you provide PV training?"
Ask:
"Show us the training records for employees who may receive safety information and explain how competency is assessed."
Instead of asking:
"Do you control your subcontractors?"
Ask:
"Which third parties currently perform activities related to our products, and how do you qualify and monitor them?"
This evidence-based approach provides a much more accurate picture of the distributor's actual compliance capability.
How PV Solutions Limited Supports Overseas MAHs
At PV Solutions Limited, we help international pharmaceutical companies evaluate and strengthen their China partner oversight.
Our China distributor audit services can be tailored to the responsibilities delegated to each local partner.
Our audits may include:
Distributor qualification audits
Annual quality audits
GxP compliance assessments
Pharmacovigilance interface audits
GDP/GSP compliance reviews
Quality system audits
Third-party oversight assessments
CAPA effectiveness reviews
Quality agreement assessments
Regulatory inspection readiness
We take a risk-based approach rather than applying a generic distributor checklist.
Our objective is to help overseas MAHs understand not only whether a Chinese distributor is compliant today, but whether the organization has the systems and capabilities necessary to remain compliant.
From "Trust" to Demonstrable Oversight
A strong relationship with a Chinese distributor is valuable.
But regulatory compliance should never depend solely on trust.
For overseas MAHs, effective governance requires:
Qualification → Contractual Responsibilities → Ongoing Monitoring → Annual Audit → CAPA → Follow-up
This creates a continuous oversight cycle rather than a one-time partner qualification exercise.
As China's regulatory expectations continue to develop, international pharmaceutical companies should increasingly view their Chinese distributors as critical outsourced partners requiring active quality oversight.
An annual, risk-based distributor audit provides an effective mechanism for maintaining that oversight and identifying potential compliance risks before they become regulatory problems.
Conclusion
Your Chinese distributor may be an important commercial partner—but that does not mean the distributor should become a "black box" between the overseas MAH and the Chinese market.
The MAH needs visibility.
It needs evidence.
And most importantly, it needs a mechanism to demonstrate that outsourced activities remain under effective control.
For overseas MAHs operating in China, annual distributor audits are not simply a quality exercise. They are an important part of regulatory risk management, GxP governance, and sustainable China compliance.
At PV Solutions Limited, we help international pharmaceutical companies strengthen oversight of their China distributors and other critical local partners through practical, risk-based audit solutions.
Need to assess your Chinese distributor or local partner? Contact PV Solutions Limited to discuss a risk-based China distributor audit tailored to your product and regulatory responsibilities.
References
Drug Administration Law of the People's Republic of China, particularly Articles 30–38
Good Supply Practice for Drugs (GSP)
Provisions for the Supervision and Administration of Drug Manufacturing
Interim Provisions on the Management of Designated Domestic Responsible Persons by Overseas Marketing Authorization Holders
The Drug Administration Law specifically requires overseas MAHs to designate a domestic legal entity and provides for regular auditing of drug distributors' quality management systems. The NMPA's designated domestic responsible person framework has applied since July 1, 2025, making clear role allocation and oversight increasingly important for overseas MAHs.
Contact PV Solutions Limited to discuss audit solutions tailored for your distributors in China.